Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to oral therapy ...

The Weill Cancer Hub East has been established to explore the “interplay” between nutrition and immunotherapy in cancer ...

The Macau Special Administrative Region (ISAF) Pharmaceutical Administration Bureau has approved IASO Biotherapeutics’ new ...

Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in ...

Genmab has received approval from Japan's Ministry of Health, Labour and Welfare for its Tivdak to treat cervical cancer.

The US Food and Drug Administration (FDA) will see the biggest cuts, with 19% of jobs in the agency being eliminated.

Bioconjugation presents an new frontier for pharmaceutical development, providing an option for improved drug efficacy across ...

A total of 29 new blockbuster-in-waiting drugs entered the late-stage pipeline in 2024, a jump from the previous year’s 19.

Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as ...

Download our guide to the digital therapeutics landscape, key providers, and market trends. Discover how digital health solutions can enhance pharmaceutical outcomes.

Ionis has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise olezarsen.

Multinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.